Source: Clin Cancer Res; 16(7); 2138–46
Authors: Anthony C. Nichols et al.

Purpose:
Oropharyngeal squamous cell carcinoma (OPSCC) associated with human papilloma virus (HPV) is rapidly growing in incidence. Despite better prognosis than OPSCC associated with traditional risk factors, treatment failure still occurs in a significant proportion of patients. We had identified the antiapoptotic protein Bcl2 as a marker for poor outcome in advanced OPSCC treated with concurrent chemoradiation. To determine whether Bcl2 and HPV together might further characterize treatment response, we examined whether the prognostic value of Bcl2 was independent of HPV status.

Experimental Design:
Pretreatment tumor biopsies from 68 OPSCC patients were tested for HPV by in situ hybridization and were immunostained for Bcl2 to evaluate relations with disease-free (DFS) and overall survival following platin-based concurrent chemoradiation. Median follow-up among surviving patients was 47 months (range, 10-131 months).

Results:
Bcl2 and HPV independently predicted DFS and overall survival. Hazard ratios (with 95% confidence interval) for positive versus negative status in bivariate Cox proportional hazard analysis of DFS were 6.1 (1.8-21) for Bcl2 and 0.11 (0.035-0.37) for HPV. Only 1 of 32 HPV-positive/Bcl2-negative tumors recurred. Pretreatment Bcl2 expression was specifically associated with distant metastasis; five of six distant metastases occurred in the <40% of patients whose primary tumors were Bcl2 positive.

Conclusions:
Independent of HPV status, pretreatment Bcl2 expression identifies a subset of OPSCC patients having increased risk of treatment failure, particularly through distant metastasis, after concurrent chemoradiation. Considering HPV and Bcl2 together should help in devising better personalized treatments for OPSCC.

Note: Supplementary data for this article are available at Clinical Cancer Research Online .

Authors:
Anthony C. Nichols1, Dianne M. Finkelstein2,3, William C. Faquin4, William H. Westra8, Edmund A. Mroz3,5, Peter Kneuertz1, Shahnaz Begum8, William A. Michaud3,5, Paul M. Busse6, John R. Clark7, and James W. Rocco1,3,5

Authors’ affiliations:
1 Department of Otolaryngology, Massachusetts Eye and Ear Infirmary; .
2 Biostatistics Center,
3 Cancer Center, and Departments of
4 Pathology,
5 Surgery,
6 Radiation Oncology, and
7 Medicine, Massachusetts General Hospital, Boston Massachusetts;
8 Department of Pathology, Johns Hopkins University, Baltimore Maryland